Treating Prostate Cancer by Antibody–Drug Conjugates

Treating Prostate Cancer by Antibody–Drug Conjugates

Prostate cancer is the most frequent malignancy in the worldwide male population; it is also one of the most common among all the leading cancer-related death causes. In the last two decades, the therapeutic scenario of metastatic castration-resistant prostate cancer has been enriched by the use of...

Full description

Bibliographic Details
Main Authors: Matteo Rosellini, Matteo Santoni, Veronica Mollica, Alessandro Rizzo, Alessia Cimadamore, Marina Scarpelli, Nadia Storti, Nicola Battelli, Rodolfo Montironi, Francesco Massari
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:International Journal of Molecular Sciences
Subjects:
prostate cancer
antibody drug conjugates
target therapy
PSMA
STEAP1
TROP2
Online Access:https://www.mdpi.com/1422-0067/22/4/1551

Internet

https://www.mdpi.com/1422-0067/22/4/1551

Similar Items